A phase I study of Cannabidiol/tetrahydrocannabinol (MedChew-1502) for the treatment of Parkinson's disease
Latest Information Update: 11 Nov 2016
Price :
$35 *
At a glance
- Drugs Nabiximols (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- 11 Nov 2016 New trial record